Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect

Abstract

BackgroundThe interleukin-17 (IL-17) family contains six homologous genes, IL-17A to IL-17F. Growing evidence indicates that dysregulated IL-17 family members act as major pathogenic factors in the early and late stages of cancer development and progression. However, the prevalence and predictive value of IL-17 for immune checkpoint inhibitor (ICI) therapeutic effectiveness in multiple tumor types remain largely unknown, and the associations between its expression levels and immunotherapy-associated signatures also need to be explored.MethodsThe pan-cancer dataset in The Cancer Genome Atlas (TCGA) was downloaded from UCSC Xena (http://xena.ucsc.edu/). The immunotherapeutic cohorts included IMvigor210, which were obtained from the Gene Expression Omnibus database and included in a previously published study. Other datasets, namely, the GEO dataset and PRECOG, GEO, and METABRIC databases, were also included. In 33 TCGA tumor types, a pan-cancer analysis was carried out including their expression map, clinical risk assessment, and immune subtype analysis, along with their association with the stemness indices, tumor microenvironment (TME) in pan-cancer, immune infiltration analysis, ICI-related immune indicators, and drug sensitivity. RT-PCR was also carried out to verify the gene expression levels among MCF-10A and MCF-7 cell lines.ResultsThe expression of the IL-17 family is different between tumor and normal tissue in most cancers, and consistency has been observed between gene activity and gene expression. RT-PCR results show that the expression differences in the IL-17 family of human cell (MCF-10A and MCF-7) are consistent with the bioinformatics differential expression analysis. Moreover, the expression of the IL-17 family can be a sign of patients’ survival prognosis in some tumors and varies in different immune subtypes. Moreover, the expression of the IL-17 family presents a robust correlation with immune cell infiltration, ICI-related immune indicators, and drug sensitivity. High expression of the IL-17 family is significantly related to immune-relevant pathways, and the low expression of IL-17B means a better immunotherapeutic response in BLCA.ConclusionCollectively, IL-17 family members may act as biomarkers in predicting the prognosis of the tumor and the therapeutic effects of ICIs, which provides new guidance for cancer treatment.

Toripalimab plus chemotherapy and radiotherapy for treatment-naive, advanced esophageal squamous cell carcinoma: A single-arm phase II trial

“…IL-4, IL-10, and TNF-α play multifaceted roles in cancer immunity, both activating antitumor immune cells and facilitating tumor immune suppression and escape. IL-10, IL-17, and TNF-α, known for their immunosuppressive properties, promote tumor growth and are associated with poor prognoses, as corroborated by several clinical studies, whereas IL-4 is considered an enhancer of immune cell antitumor activity [41][42][43][44]. Our results showed that higher baseline levels of IL-4, IL-10, and IFN-λ, as well as elevated treatment levels of IFN-λ, TNF-α, and IL-17, were associated with improved OS.…”

M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma

“…Tumor-associated macrophages are an important part of tumor immune microenvironment ( 19 ), which are usually divided into two types, one is M1 macrophages, which are involved in inflammation and can kill cancer cells, and the other is M2 macrophage, which can promote tumor progression. Many studies have shown that, on the one hand, the abundance of macrophages in tumors is negatively correlated with the prognosis and survival of patients, and on the other hand, it is positively correlated with tumor drug resistance ( 20 , 21 ). It has been previously reported that in the early stage of tumor development, macrophages in TME are mainly M1 phenotype ( 22 ).…”

GADD45B regulates the carcinogenesis process of chronic atrophic gastritis and the metabolic pathways of gastric cancer

“…To illustrate the results of the drug sensitivity analysis, we used box plots to visualize the dispersion of IC50 values across multiple samples. Additionally, we examined the correlation between the model score and IC50 to assess the relationship between CRG expression and drug sensitivity ( 55 ). By conducting these analyses, we aimed to explore the clinical implications of CRG in gastric cancer patients, including its associations with patient characteristics and its potential role in predicting the response to common chemotherapy regimens.…”